https://www.pharmaradar360.com/article/shinsa-considerations-for-the-clinical-evaluation-of-blood-coagulation-factor-vi-01c129eaa8bd1ee0Pharma Surgeen2026-07-24T03:00:00.000Z[SHINSA]Considerations for the Clinical Evaluation of Blood Coagulation Factor VIII and Factor IX Products for Pediatric Congenital Hemophilia (Early Consideration) posted.https://www.pharmaradar360.com/article/novocure-nvcr-breaks-out-on-q2-2026-earnings-optune-pax-driving-recovery-d29aa8bbd69d100aPharma Surgeen2026-07-24T02:02:41.000ZNovoCure (NVCR) Breaks Out on Q2 2026 Earnings - Optune Pax Driving Recoveryhttps://www.pharmaradar360.com/article/gene-editor-scribe-therapeutics-starts-second-half-ipo-spree-with-129m-listing-6f2ba6f10ab00215Pharma Surgeen2026-07-24T02:01:00.000ZGene editor Scribe Therapeutics starts second-half IPO spree with $129M listinghttps://www.pharmaradar360.com/article/fda-panel-recommends-loosening-restrictions-on-peptides-despite-scientists-conce-cc1cdb16df7c1d96Pharma Surgeen2026-07-24T01:32:10.000ZFDA panel recommends loosening restrictions on peptides, despite scientists’ concernshttps://www.pharmaradar360.com/article/scribe-secures-129m-in-a-rare-gene-editing-ipo-83ef5b880ea7bbd9Pharma Surgeen2026-07-24T01:30:06.000ZScribe secures $129M in a rare gene editing IPOhttps://www.pharmaradar360.com/article/arkbio-completes-all-cohort-dosing-in-australian-phase-i-trial-with-influenza-af-e547afb5c565c6a0Pharma Surgeen2026-07-24T01:29:22.000ZArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406https://www.pharmaradar360.com/article/china-s-biotech-innovation-fuels-merck-s-long-term-healthcare-bet-e48e9fcdd4954834Pharma Surgeen2026-07-24T01:15:32.000ZChina's biotech innovation fuels Merck's long-term healthcare bethttps://www.pharmaradar360.com/article/dimerix-secures-10-million-for-its-phase-3-kidney-trial-and-adds-a-new-asset-4d643a9daeb838e2Pharma Surgeen2026-07-24T01:14:00.000ZDimerix Secures $10 Million for Its Phase 3 Kidney Trial—and Adds a New Assethttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-stock-up-3-4-but-gf-v-fbca6b588f4949e7Pharma Surgeen2026-07-24T00:33:45.000ZTeva Pharmaceutical Industries Ltd (TEVA) Stock Up 3.4% but GF Vhttps://www.pharmaradar360.com/article/krystal-biotech-inc-nasdaqgs-krys-added-to-s-p-400-biotechnology-741ccb8ec8b605dbPharma Surgeen2026-07-24T00:23:39.000ZKrystal Biotech, Inc.(NasdaqGS: KRYS) added to S&P 400 - Biotechnologyhttps://www.pharmaradar360.com/article/krystal-biotech-inc-nasdaqgs-krys-added-to-s-p-400-health-care-7d5a9acb719e54e9Pharma Surgeen2026-07-24T00:23:32.000ZKrystal Biotech, Inc.(NasdaqGS: KRYS) added to S&P 400 Health Carehttps://www.pharmaradar360.com/article/krystal-biotech-inc-nasdaqgs-krys-dropped-from-s-p-600-health-care-a74c831e6c79fdf2Pharma Surgeen2026-07-24T00:23:08.000ZKrystal Biotech, Inc.(NasdaqGS: KRYS) dropped from S&P 600 Health Carehttps://www.pharmaradar360.com/article/krystal-biotech-inc-nasdaqgs-krys-dropped-from-s-p-600-8516518ad722849ePharma Surgeen2026-07-24T00:22:59.000ZKrystal Biotech, Inc.(NasdaqGS: KRYS) dropped from S&P 600https://www.pharmaradar360.com/article/boston-biotech-company-creates-perfumes-inspired-by-extinct-flowers-and-clouds-0de755f7c7d31967Pharma Surgeen2026-07-24T00:21:17.000ZBoston biotech company creates perfumes inspired by extinct flowers and cloudshttps://www.pharmaradar360.com/article/neuren-pharmaceuticals-advances-phase-3-koala-trial-for-phelan-mcdermid-syndrome-a589b19305c918e5Pharma Surgeen2026-07-24T00:06:18.000ZNeuren Pharmaceuticals Advances Phase 3 Koala Trial for Phelan-McDermid Syndrome as Presenting Sponsor of Family Conferencehttps://www.pharmaradar360.com/article/kdca-submits-phase-2-ind-for-domestic-mrna-covid-19-vaccine-4e5202c28ec13bbdPharma Surgeen2026-07-24T00:03:03.000ZKDCA Submits Phase 2 IND for Domestic mRNA COVID-19 Vaccinehttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-f10ce9f887436584Pharma Surgeen2026-07-24T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-a624b99571276987Pharma Surgeen2026-07-24T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-3fa24f78dc61eb65Pharma Surgeen2026-07-24T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-e0605449c7ed9b2bPharma Surgeen2026-07-24T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-e8e599cd5f54127aPharma Surgeen2026-07-24T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-12aba7eab868ce90Pharma Surgeen2026-07-24T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-2a45c799886ecfa2Pharma Surgeen2026-07-24T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-a3c1e35b69ea6175Pharma Surgeen2026-07-24T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-ffedcdc25c48c60aPharma Surgeen2026-07-24T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-896ae89b16a77895Pharma Surgeen2026-07-24T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-17d14f7146ee87c9Pharma Surgeen2026-07-24T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-dd8bf244af827b9ePharma Surgeen2026-07-24T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-c2bb5f6213d6fcccPharma Surgeen2026-07-24T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-27b9c4104a97479ePharma Surgeen2026-07-24T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/prognostic-significance-of-stem-cell-markers-in-triple-negative-breast-cancers-5543077e138735a6Pharma Surgeen2026-07-24T00:00:00.000ZPrognostic significance of stem cell markers: In triple-negative breast cancershttps://www.pharmaradar360.com/article/cross-sectional-survey-of-factors-influencing-treatment-adherence-in-elderly-can-1b8cfc514dc2b18cPharma Surgeen2026-07-24T00:00:00.000ZCross-sectional survey of factors influencing treatment adherence in elderly cancer patients in rural mountainous Guangyuan, Chinahttps://www.pharmaradar360.com/article/predictive-value-of-peripheral-blood-systemic-immune-inflammation-index-and-bloo-6334bb33041bc6f1Pharma Surgeen2026-07-24T00:00:00.000ZPredictive value of peripheral blood systemic immune-inflammation index and blood cell ratio for gastrointestinal polyp burden in patients with Peutz-Jeghers syndromehttps://www.pharmaradar360.com/article/letter-to-the-editor-beyond-cyst-size-a-time-risk-state-framework-for-dynamic-su-46630034a32a54cbPharma Surgeen2026-07-24T00:00:00.000ZLetter to the Editor: Beyond cyst size - a time-risk-state framework for dynamic surveillance de-escalation of branch duct intraductal papillary mucinous neoplasmshttps://www.pharmaradar360.com/article/multicenter-nomogram-integrating-clinicopathological-features-for-prognosis-in-s-00f95ee97dcac1b6Pharma Surgeen2026-07-24T00:00:00.000ZMulticenter nomogram integrating clinicopathological features for prognosis in stage II-III deficient/microsatellite instability-high rectal cancerhttps://www.pharmaradar360.com/article/metastasis-to-the-adrenal-glands-an-update-1c342ae391d72698Pharma Surgeen2026-07-24T00:00:00.000ZMetastasis to the adrenal glands: An updatehttps://www.pharmaradar360.com/article/harnessing-minimal-residual-disease-for-precision-medicine-in-locally-advanced-g-8445d72d01f197d5Pharma Surgeen2026-07-24T00:00:00.000ZHarnessing minimal residual disease for precision medicine in locally advanced gastric cancerhttps://www.pharmaradar360.com/article/multidimensional-mechanisms-of-drug-resistance-in-non-small-cell-lung-cancer-and-bfff4e2b25c30aa2Pharma Surgeen2026-07-24T00:00:00.000ZMultidimensional mechanisms of drug resistance in non-small cell lung cancer and novel strategies for overcoming ithttps://www.pharmaradar360.com/article/copper-homeostasis-imbalance-and-cuproptosis-emerging-targets-and-strategies-for-294fae5197491e37Pharma Surgeen2026-07-24T00:00:00.000ZCopper homeostasis imbalance and cuproptosis: Emerging targets and strategies for gastrointestinal tumor therapyhttps://www.pharmaradar360.com/article/determinants-of-magnetic-resonance-imaging-overstaging-in-rectal-cancer-t-stagin-3e6f713f6cbf0ccePharma Surgeen2026-07-24T00:00:00.000ZDeterminants of magnetic resonance imaging overstaging in rectal cancer T-staginghttps://www.pharmaradar360.com/article/whole-exome-sequencing-identification-of-the-risk-variants-in-a-middle-aged-adul-2ce2f3c5829e74cdPharma Surgeen2026-07-24T00:00:00.000ZWhole-exome sequencing identification of the risk variants in a middle-aged adult with intracranial Ewing’s sarcoma: A case reporthttps://www.pharmaradar360.com/article/letter-to-the-editor-cancer-stem-cell-and-oncomatrix-biomarkers-predict-chemothe-1ea035c2dff95134Pharma Surgeen2026-07-24T00:00:00.000ZLetter to the Editor: Cancer stem cell and oncomatrix biomarkers predict chemotherapy response and survival in triple-negative breast cancerhttps://www.pharmaradar360.com/article/letter-to-the-editor-patient-reported-outcomes-of-intensity-modulated-radiothera-5c859dd53d203922Pharma Surgeen2026-07-24T00:00:00.000ZLetter to the Editor: Patient-reported outcomes of intensity-modulated radiotherapy <i>vs</i> three-dimensional conformal radiotherapy in prostate cancerhttps://www.pharmaradar360.com/article/emergence-of-human-epidermal-growth-factor-receptor-2-as-a-key-biomarker-and-the-0923b93d6b424ddfPharma Surgeen2026-07-24T00:00:00.000ZEmergence of human epidermal growth factor receptor 2 as a key biomarker and therapeutic target in advanced urothelial carcinomahttps://www.pharmaradar360.com/article/profile-of-antidepressant-use-and-drug-interactions-among-psychiatric-outpatient-348df566913b334ePharma Surgeen2026-07-24T00:00:00.000ZProfile of Antidepressant Use and Drug Interactions among Psychiatric Outpatients at RSUD Ainun Habibiehttps://www.pharmaradar360.com/article/psychometric-validity-and-clinical-utility-of-the-ghq-12-for-screening-psycholog-886e10b0feecc0a3Pharma Surgeen2026-07-24T00:00:00.000ZPsychometric validity and clinical utility of the GHQ-12 for screening psychological health in isolated, confined and unusual or extreme environmentshttps://www.pharmaradar360.com/article/treatment-of-typical-and-atypical-trigeminal-neuralgia-with-linac-based-radiosur-9596e01e087b7f6cPharma Surgeen2026-07-24T00:00:00.000ZTreatment of Typical and Atypical Trigeminal Neuralgia with LINAC-Based Radiosurgery: Complications, Recurrence Rates and Long-Term Treatment Outcomeshttps://www.pharmaradar360.com/article/factors-associated-with-clinical-severity-in-scorpion-envenomation-a-retrospecti-dd7c3000139c83e0Pharma Surgeen2026-07-24T00:00:00.000ZFactors associated with clinical severity in scorpion envenomation: a retrospective cross-sectional study in western Mexico between 2021 and 2025https://www.pharmaradar360.com/article/effects-of-platelet-lysate-on-the-rate-of-orthodontic-tooth-movement-a-single-ce-62327f4a5257af16Pharma Surgeen2026-07-24T00:00:00.000ZEffects of platelet lysate on the rate of orthodontic tooth movement: a single-center, split-mouth, randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-comparison-of-different-debonding-techniques-of-clear-aligner-attachmen-25239f91748d5decPharma Surgeen2026-07-24T00:00:00.000ZClinical comparison of different debonding techniques of clear aligner attachments: a single-center, split-mouth randomized clinical trialhttps://www.pharmaradar360.com/article/impact-of-tnf-alpha-308-g-a-polymorphism-on-response-to-tnf-inhibitors-in-tunisi-46dfb349942b8effPharma Surgeen2026-07-24T00:00:00.000ZImpact of TNF-alpha -308 G/A polymorphism on response to TNF inhibitors in Tunisian patients with inflammatory rheumatic diseaseshttps://www.pharmaradar360.com/article/clinical-factors-related-to-cardiac-conduction-disturbance-in-patients-with-wild-1960f220eca28d40Pharma Surgeen2026-07-24T00:00:00.000ZClinical Factors Related to Cardiac Conduction Disturbance in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy Undergoing Tafamidis Treatmenthttps://www.pharmaradar360.com/article/beyond-strut-coverage-toward-functional-endothelization-after-drug-eluting-stent-6c917b5b363406d7Pharma Surgeen2026-07-24T00:00:00.000ZBeyond Strut Coverage ― Toward Functional Endothelization After Drug-Eluting Stent Implantation ―https://www.pharmaradar360.com/article/clinical-outcomes-after-drug-eluting-stent-thrombosis-in-patients-on-hemodialysi-7bb001e7fe7e3fd6Pharma Surgeen2026-07-24T00:00:00.000ZClinical Outcomes After Drug-Eluting Stent Thrombosis in Patients on Hemodialysis ― Insights From the REAL-ST Registry ―https://www.pharmaradar360.com/article/assessment-of-and-factors-contributing-to-adequate-endothelization-after-drug-el-6cee74832917826ePharma Surgeen2026-07-24T00:00:00.000ZAssessment of and Factors Contributing to Adequate Endothelization After Drug-Eluting Stent Implantationhttps://www.pharmaradar360.com/article/aspirin-vs-clopidogrel-monotherapy-beyond-1-month-after-percutaneous-coronary-in-52b0c47c18c75d34Pharma Surgeen2026-07-24T00:00:00.000ZAspirin vs. Clopidogrel Monotherapy Beyond 1 Month After Percutaneous Coronary Intervention in Patients With Diabetes ― Prespecified Subgroup Analysis of the STOPDAPT-3 Trial ―https://www.pharmaradar360.com/article/a-phenylbutyrate-derived-nitric-oxide-donor-induces-pancreatic-cancer-cell-death-2f5e8a07ae4649ffPharma Surgeen2026-07-24T00:00:00.000ZA Phenylbutyrate-Derived Nitric Oxide Donor Induces Pancreatic Cancer Cell Death Accompanied by Impairment of Autophagy-Related Pathways and HIF-1&lt;i&gt;α&lt;/i&gt; Reductionhttps://www.pharmaradar360.com/article/preventive-effects-of-non-sedating-and-sedating-histamine-h-lt-sub-gt-1-lt-sub-g-da58c9a8e8c6b686Pharma Surgeen2026-07-24T00:00:00.000ZPreventive Effects of Non-sedating and Sedating Histamine H&lt;sub&gt;1&lt;/sub&gt; Receptor Antagonists Premedication for Subcutaneous Daratumumab-Associated Infusion-Related Reactions: A Prospective Observational Studyhttps://www.pharmaradar360.com/article/heart-rate-variability-in-adhd-a-clinical-perspective-on-autonomic-regulation-em-257dc0306ac167a1Pharma Surgeen2026-07-24T00:00:00.000ZHeart rate variability in ADHD: a clinical perspective on autonomic regulation, emotional dysregulation, and treatment tolerabilityhttps://www.pharmaradar360.com/article/stress-diet-and-aging-a-comprehensive-analysis-of-allostatic-load-in-biological-bcfcea25b0acd7d8Pharma Surgeen2026-07-24T00:00:00.000ZStress, diet, and aging: a comprehensive analysis of allostatic load in biological aginghttps://www.pharmaradar360.com/article/evaluating-performance-and-potential-clinical-benefit-of-the-swedish-on-scene-in-304df2e3f5d3d591Pharma Surgeen2026-07-24T00:00:00.000ZEvaluating performance and potential clinical benefit of the Swedish On Scene Injury Severity Prediction (OSISP) model for prehospital field triage on Norwegian trauma datahttps://www.pharmaradar360.com/article/fourth-annual-workshop-on-fetal-alcohol-spectrum-disorders-prevention-and-clinic-3ea4cd446842d719Pharma Surgeen2026-07-24T00:00:00.000ZFourth annual workshop on fetal alcohol spectrum disorders prevention and clinical guidelines research: co-occurring conditionshttps://www.pharmaradar360.com/article/nursing-students-first-clinical-encounters-with-delirium-a-qualitative-study-of-909a57069d4cd508Pharma Surgeen2026-07-24T00:00:00.000ZNursing students’ first clinical encounters with delirium: a qualitative study of experiential learning and professional developmenthttps://www.pharmaradar360.com/article/social-responsibility-and-professional-accountability-in-clinical-nursing-practi-e86bacc2ce0778a9Pharma Surgeen2026-07-24T00:00:00.000ZSocial responsibility and professional accountability in clinical nursing practice: a correlational analysishttps://www.pharmaradar360.com/article/tooth-brushing-versus-routine-oral-care-impact-on-ventilator-associated-pneumoni-1944e4c3f65e51ecPharma Surgeen2026-07-24T00:00:00.000ZTooth brushing versus routine oral care impact on ventilator-associated pneumonia in PICU: a clinical trialhttps://www.pharmaradar360.com/article/preventing-content-leakage-in-llm-based-medical-rag-structure-only-retrieval-for-1ae4758356752427Pharma Surgeen2026-07-24T00:00:00.000ZPreventing Content Leakage in LLM-Based Medical RAG: Structure-Only Retrieval for Faithful Clinical Summarizationhttps://www.pharmaradar360.com/article/government-donor-academia-collaboration-model-in-the-pharmaceutical-regulatory-s-313bbe42250bd0dcPharma Surgeen2026-07-24T00:00:00.000ZGovernment–donor–academia collaboration model in the pharmaceutical regulatory system and considerations for sustainability in low- and middle-income countrieshttps://www.pharmaradar360.com/article/guest-editorial-taking-hybridity-seriously-in-drug-market-research-e793971493693c1ePharma Surgeen2026-07-24T00:00:00.000ZGuest editorial: Taking hybridity seriously in drug market researchhttps://www.pharmaradar360.com/article/fingernail-squamous-cell-carcinoma-a-scoping-review-of-surgical-approaches-and-c-921eff33677d3aedPharma Surgeen2026-07-24T00:00:00.000ZFingernail Squamous Cell Carcinoma: A Scoping Review of Surgical Approaches and Clinical Decision Makinghttps://www.pharmaradar360.com/article/the-role-of-skin-surface-ph-in-age-associated-pruritus-mechanistic-and-clinical-390ed47166bea76aPharma Surgeen2026-07-24T00:00:00.000ZThe Role of Skin Surface pH in Age Associated Pruritus: Mechanistic and Clinical Insightshttps://www.pharmaradar360.com/article/fda-panel-narrowly-backs-unapproved-peptide-drugs-favored-by-rfk-jr-and-wellness-409663643b58d656Pharma Surgeen2026-07-23T23:07:35.000ZFDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencershttps://www.pharmaradar360.com/article/west-pharmaceutical-wst-receives-strong-outlook-amidst-quarterly-performance-d717b31cbde40ae1Pharma Surgeen2026-07-23T22:52:30.000ZWest Pharmaceutical (WST) Receives Strong Outlook Amidst Quarterly Performancehttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-sa-sdmhf-q2-2026-earnings-call-highli-d324d110648c1f86Pharma Surgeen2026-07-23T22:41:15.000ZSartorius Stedim Biotech SA (SDMHF) Q2 2026 Earnings Call Highlihttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-stock-up-3-4-but-gf-v-b59ca1d024912646Pharma Surgeen2026-07-23T22:32:42.000ZTeva Pharmaceutical Industries Ltd (TEVA) Stock Up 3.4% but GF Vhttps://www.pharmaradar360.com/article/fda-panel-narrowly-backs-unapproved-peptide-drugs-favored-by-rfk-jr-3e0188690890d027Pharma Surgeen2026-07-23T22:09:05.000ZFDA panel narrowly backs unapproved peptide drugs favored by RFK Jr.https://www.pharmaradar360.com/article/virginia-biotech-lab-expands-to-support-life-sciences-growth-b2c03684f7e732e0Pharma Surgeen2026-07-23T21:36:52.000ZVirginia Biotech Lab Expands To Support Life Sciences Growthhttps://www.pharmaradar360.com/article/genmab-and-abbvie-provide-clarification-on-phase-3-epcore-dlbcl-1-trial-evaluati-12dac9f850a16c25Pharma Surgeen2026-07-23T21:26:23.000ZGenmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphomahttps://www.pharmaradar360.com/article/young-calls-for-passage-of-his-bill-to-crack-down-on-fraudsters-d105c91f80b87333Pharma Surgeen2026-07-23T21:11:15.000ZYoung Calls for Passage of His Bill to Crack Down on Fraudstershttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-q2-2026-earnings-call-summary-6445afea2415c9a6Pharma Surgeen2026-07-23T21:08:48.000ZWest Pharmaceutical Services, Inc. Q2 2026 Earnings Call Summaryhttps://www.pharmaradar360.com/article/not-scientifically-supportable-inside-fda-s-refusal-to-face-us-generic-drug-cris-cbc7043c0f196404Pharma Surgeen2026-07-23T21:03:32.000Z'Not scientifically supportable:' Inside FDA’s refusal to face US generic drug crisishttps://www.pharmaradar360.com/article/krystal-biotech-sets-aug-3-webcast-before-u-s-markets-open-22ea3ef61acc7414Pharma Surgeen2026-07-23T21:02:24.000ZKrystal Biotech sets Aug. 3 webcast before U.S. markets openhttps://www.pharmaradar360.com/article/not-scientifically-supportable-inside-fda-s-refusal-to-face-us-generic-drug-cris-a9eede42d5f54991Pharma Surgeen2026-07-23T21:00:19.000Z'Not scientifically supportable:' Inside FDA’s refusal to face US generic drug crisishttps://www.pharmaradar360.com/article/ishares-global-healthcare-etf-vs-vaneck-biotech-etf-which-etf-is-better-for-prof-52d14eefe4b2b5afPharma Surgeen2026-07-23T20:30:00.000ZiShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?https://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-2q-2026-revenue-872-3m-eps-2-15-10-q-summary-4eca68edc293b84dPharma Surgeen2026-07-23T20:21:01.000ZWest Pharmaceutical Services Inc 2Q 2026: Revenue $872.3M, EPS $2.15— 10-Q Summaryhttps://www.pharmaradar360.com/article/an-fda-committee-just-voted-in-favor-of-peptides-despite-the-agency-s-opposition-9a77905bc2d90a05Pharma Surgeen2026-07-23T20:19:08.000ZAn FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Oppositionhttps://www.pharmaradar360.com/article/10-q-west-pharmaceutical-services-inc-quarterly-earnings-report-1f39e9034ecd4c0fPharma Surgeen2026-07-23T20:16:23.000Z[10-Q] WEST PHARMACEUTICAL SERVICES INC Quarterly Earnings Reporthttps://www.pharmaradar360.com/article/codexis-announces-proposed-public-offering-of-common-stock-24d2bac48eb5ceddPharma Surgeen2026-07-23T20:13:00.000ZCodexis Announces Proposed Public Offering of Common Stockhttps://www.pharmaradar360.com/article/eli-lilly-reports-positive-results-from-two-phase-iii-trials-pharmexec-467bf75b8231c7ddPharma Surgeen2026-07-23T20:10:50.000ZEli Lilly Reports Positive Results from Two Phase III Trials | PharmExechttps://www.pharmaradar360.com/article/exozymes-selected-for-doe-s-genesis-mission-to-advance-ai-powered-digital-twins-e83ab04fcdf19644Pharma Surgeen2026-07-23T20:10:38.000ZeXoZymes selected for DoE’s Genesis Mission to advance AI-powered digital twins for cell-free biomanufacturinghttps://www.pharmaradar360.com/article/genmab-and-abbvie-provide-clarification-on-phase-3-epcore-dlbcl-1-trial-evaluati-9cbd5d3021b6ca6fPharma Surgeen2026-07-23T20:10:06.000ZGenmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)https://www.pharmaradar360.com/article/twin-phase-3-studies-recruiting-adults-with-lupus-skin-problems-in-us-canada-4eb37716679f1275Pharma Surgeen2026-07-23T20:05:06.000ZTwin Phase 3 studies recruiting adults with lupus skin problems in US, Canadahttps://www.pharmaradar360.com/article/genmab-and-abbvie-provide-clarification-on-phase-3-epcore-dlbcl-1-trial-evaluati-e9b83c71f5a528b7Pharma Surgeen2026-07-23T20:05:00.000ZGenmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)https://www.pharmaradar360.com/article/west-pharma-says-sterile-packaging-upgrades-fuel-demand-for-high-value-plastics-d28e8d868691cffdPharma Surgeen2026-07-23T19:57:00.000ZWest Pharma says sterile packaging upgrades fuel demand for high-value plasticshttps://www.pharmaradar360.com/article/ishares-global-healthcare-etf-vs-vaneck-biotech-etf-which-etf-is-better-for-prof-df4c0f337e072898Pharma Surgeen2026-07-23T19:53:01.000ZiShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?https://www.pharmaradar360.com/article/ishares-global-healthcare-etf-vs-vaneck-biotech-etf-which-etf-is-better-for-prof-e2664599a64aaa66Pharma Surgeen2026-07-23T19:50:19.000ZiShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?https://www.pharmaradar360.com/article/peptides-are-surging-in-popularity-what-are-they-and-do-they-work-why-doctors-ar-dfe7900758a34362Pharma Surgeen2026-07-23T19:37:04.000ZPeptides are surging in popularity. What are they, and do they work? Why doctors are urging caution.https://www.pharmaradar360.com/article/trump-plans-to-impose-100-tariffs-on-generic-drugs-starting-in-2028-what-would-t-af5865b2cff96546Pharma Surgeen2026-07-23T19:30:07.000ZTrump Plans to Impose 100% Tariffs on Generic Drugs Starting in 2028. What Would That Do to Prices?https://www.pharmaradar360.com/article/pennsylvania-biotech-center-pauses-expansion-amid-funding-crunch-a6e2f0c02b6c1fe8Pharma Surgeen2026-07-23T19:30:00.000ZPennsylvania Biotech Center pauses expansion amid funding crunchhttps://www.pharmaradar360.com/article/playing-the-biotech-breakout-with-insiders-a4e262a8f9e719bbPharma Surgeen2026-07-23T19:15:20.000ZPlaying The Biotech Breakout With Insidershttps://www.pharmaradar360.com/article/intrepidx-appoints-taylor-judd-as-director-of-business-development-to-expand-pha-f5570ed084747b3aPharma Surgeen2026-07-23T19:13:57.000ZIntrepidX Appoints Taylor Judd as Director of Business Development to Expand Pharmaceutical Litigation Practicehttps://www.pharmaradar360.com/article/west-pharmaceutical-wst-receives-strong-outlook-amidst-quarterly-performance-4cb2c607b9452061Pharma Surgeen2026-07-23T19:06:09.000ZWest Pharmaceutical (WST) Receives Strong Outlook Amidst Quarterly Performancehttps://www.pharmaradar360.com/article/update-peptides-favored-on-1st-day-of-closely-watched-fda-compounding-adcomm-18a6acbbd8589782Pharma Surgeen2026-07-23T19:05:23.000ZUPDATE: Peptides favored on 1st day of closely watched FDA compounding adcommhttps://www.pharmaradar360.com/article/food-safety-alerts-fda-wellness-reviews-and-planning-for-retirement-health-costs-6b8cb298512e876aPharma Surgeen2026-07-23T18:59:00.000ZFood safety alerts, FDA wellness reviews and planning for retirement health costshttps://www.pharmaradar360.com/article/neuphoria-therapeutics-0ff5497e40c235e1Pharma Surgeen2026-07-23T18:58:49.000ZNeuphoria Therapeuticshttps://www.pharmaradar360.com/article/agro-vert-shops-regulations-294ec4f628cb20eaPharma Surgeen2026-07-23T18:57:55.000ZAgro-vert-shops-regulationshttps://www.pharmaradar360.com/article/antibacterial-drug-partnership-accelerates-polypid-commercial-path-ecade779113b784dPharma Surgeen2026-07-23T18:51:36.000ZAntibacterial Drug Partnership Accelerates PolyPid Commercial Pathhttps://www.pharmaradar360.com/article/fda-advisory-committee-votes-to-add-popular-peptide-bpc-157-to-drug-compounding-689df6aff070bcb0Pharma Surgeen2026-07-23T18:38:38.000ZFDA advisory committee votes to add popular peptide BPC-157 to drug compounding listhttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-sa-sdmhf-q2-2026-earnings-call-highli-a66c5b7ca45a7ceePharma Surgeen2026-07-23T18:38:07.000ZSartorius Stedim Biotech SA (SDMHF) Q2 2026 Earnings Call Highlihttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-advances-bitac-tce-development-with-positive-regulatory-feed-83769e45c415dac6Pharma Surgeen2026-07-23T18:38:03.000ZVERAXA Biotech (VRXA) Advances BiTAC®-TCE Development With Positive Regulatory Feedback From Germanyhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-wst-q2-2026-earnings-call-hig-8d57ea1021bf5d27Pharma Surgeen2026-07-23T18:35:47.000ZWest Pharmaceutical Services Inc (WST) Q2 2026 Earnings Call Highttps://www.pharmaradar360.com/article/3-fragen-an-adrian-cuadra-leon-general-manager-von-ucb-alps-austria-switzerland-fa75cbcf7d60c529Pharma Surgeen2026-07-23T18:27:56.000Z3 Fragen an Adrian Cuadra Leon, General Manager von UCB ALPS (Austria & Switzerland)https://www.pharmaradar360.com/article/is-patient-affordability-better-or-worse-in-2026-260215a5050f889dPharma Surgeen2026-07-23T18:17:59.000ZIs Patient Affordability Better or Worse in 2026?https://www.pharmaradar360.com/article/wst-stock-jumps-on-q2-earnings-sales-beat-eps-view-up-on-hvp-growth-fc02032fdcb02de5Pharma Surgeen2026-07-23T18:08:00.000ZWST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growthhttps://www.pharmaradar360.com/article/a-peptide-showdown-f-d-a-scientists-may-clash-with-r-f-k-s-agenda-465349f9db30bebaPharma Surgeen2026-07-23T18:06:08.000ZA Peptide Showdown: F.D.A. Scientists May Clash With R.F.K.’s Agendahttps://www.pharmaradar360.com/article/bora-pharmaceuticals-and-onconic-therapeutics-sign-manufacturing-agreement-to-su-23b06eae9d7abbb1Pharma Surgeen2026-07-23T17:51:17.000ZBora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tabletshttps://www.pharmaradar360.com/article/canton-strategic-sells-biotech-unit-to-focus-on-blockchain-e4d2639bc14fa3bcPharma Surgeen2026-07-23T17:51:07.000ZCanton Strategic sells biotech unit to focus on blockchainhttps://www.pharmaradar360.com/article/fda-meeting-to-review-safety-and-efficacy-of-popular-peptides-amid-controversy-5b6fb3e7f03e1ab1Pharma Surgeen2026-07-23T17:37:27.000ZFDA Meeting to Review Safety and Efficacy of Popular Peptides Amid Controversyhttps://www.pharmaradar360.com/article/fda-panel-narrowly-backs-unapproved-peptide-drug-touted-by-joe-rogan-and-other-i-7cce8df693e0be84Pharma Surgeen2026-07-23T17:29:02.000ZFDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencershttps://www.pharmaradar360.com/article/why-teva-pharmaceutical-stock-is-a-buy-despite-trump-tariff-threat-cd1c471c17e2c3a0Pharma Surgeen2026-07-23T17:27:00.000ZWhy Teva Pharmaceutical Stock Is a Buy Despite Trump Tariff Threathttps://www.pharmaradar360.com/article/cell-therapy-tg-c-misses-primary-endpoints-in-phase-3-knee-osteoarthritis-trial-6b3059c51e60be2aPharma Surgeen2026-07-23T17:08:43.000ZCell Therapy TG-C Misses Primary Endpoints in Phase 3 Knee Osteoarthritis Trialhttps://www.pharmaradar360.com/article/cash-flow-from-operating-activities-of-teh-seng-pharmaceutical-mfg-co-ltd-tpex-7-1cf8f2add8d336d5Pharma Surgeen2026-07-23T16:44:18.000ZCash flow from operating activities of Teh Seng Pharmaceutical Mfg Co Ltd – TPEX:7860https://www.pharmaradar360.com/article/free-cash-flow-of-teh-seng-pharmaceutical-mfg-co-ltd-tpex-7860-dca47d78c266652cPharma Surgeen2026-07-23T16:42:52.000ZFree cash flow of Teh Seng Pharmaceutical Mfg Co Ltd – TPEX:7860https://www.pharmaradar360.com/article/lonza-with-big-vacaville-biotech-campus-reports-strong-first-half-9ca5c8fb0f65354aPharma Surgeen2026-07-23T16:33:35.000ZLonza, with big Vacaville biotech campus, reports strong first halfhttps://www.pharmaradar360.com/article/okyo-pharma-ceo-robert-dempsey-acquires-15-000-shares-at-1-54-ahead-of-phase-3-t-f66fac94c9c6eedaPharma Surgeen2026-07-23T16:31:41.000ZOKYO Pharma CEO Robert Dempsey Acquires 15,000 Shares at $1.54 Ahead of Phase 3 Trial Launchhttps://www.pharmaradar360.com/article/landscape-analysis-of-the-integration-of-ai-into-pharmaceutical-innovation-part-2581dda348aa892fPharma Surgeen2026-07-23T16:26:31.000ZLandscape Analysis of the Integration of AI into Pharmaceutical Innovation | Part 1https://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-advances-bitac-r-tce-development-with-positive-regula-d609f6d2e4db84a0Pharma Surgeen2026-07-23T16:22:40.000ZVERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germanyhttps://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-advances-bitac-r-tce-development-with-positive-regula-578cdd2559ce3b1fPharma Surgeen2026-07-23T16:22:40.000ZVERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Gehttps://www.pharmaradar360.com/article/cordis-project-centre-for-new-methods-in-computational-diagnostics-and-personali-e797013116efac62Pharma Surgeen2026-07-23T16:22:04.000ZCORDIS project: Centre for New Methods in Computational Diagnostics and Personalised Therapyhttps://www.pharmaradar360.com/article/west-pharmaceutical-beats-q2-earnings-estimates-raises-outlook-on-strong-injecta-7cd138fb3154c772Pharma Surgeen2026-07-23T16:18:25.000ZWest Pharmaceutical beats Q2 earnings estimates, raises outlook on strong injectable drug demandhttps://www.pharmaradar360.com/article/veraxa-biotech-appoints-christoph-erkel-as-chief-scientific-officer-19b16ca4aa74b453Pharma Surgeen2026-07-23T16:14:50.000ZVERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officerhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-reports-strong-q2-2026-earnin-340417ea1993ae21Pharma Surgeen2026-07-23T16:07:51.000ZWest Pharmaceutical Services (WST) Reports Strong Q2 2026 Earninhttps://www.pharmaradar360.com/article/eu-pharmaceutical-law-forum-key-insights-2026-aa3922fe82409b06Pharma Surgeen2026-07-23T16:05:55.000ZEU Pharmaceutical Law Forum: Key Insights 2026https://www.pharmaradar360.com/article/immunovant-to-report-financial-results-for-the-first-quarter-ended-june-30-2026-9846d23058f8b206Pharma Surgeen2026-07-23T16:05:00.000ZImmunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026https://www.pharmaradar360.com/article/biotech-is-back-baby-a-wave-of-life-science-deals-is-pumping-cash-into-the-secto-8e43f59d3e4ff60cPharma Surgeen2026-07-23T16:04:19.000ZBiotech is back, baby! A wave of life science deals is pumping cash into the sector.https://www.pharmaradar360.com/article/okyo-pharma-director-s-holding-reaches-35-201-shares-364a0b10bcb653ddPharma Surgeen2026-07-23T16:00:00.000ZOKYO Pharma Director's Holding Reaches 35,201 Shareshttps://www.pharmaradar360.com/article/gerresheimer-starts-operations-at-new-plant-in-zhenjiang-dagang-china-112363e514a93153Pharma Surgeen2026-07-23T15:55:48.000ZGerresheimer Starts Operations at New Plant in Zhenjiang Dagang, Chinahttps://www.pharmaradar360.com/article/polypid-azurity-sign-us-330m-deal-for-d-plex100-ddcae2910c7b75dfPharma Surgeen2026-07-23T15:45:52.000ZPolyPid, Azurity Sign US$330M Deal for D-PLEX100https://www.pharmaradar360.com/article/lilly-with-new-data-to-seek-fda-approval-of-obesity-drug-retatrutide-4129a86a43e10bd5Pharma Surgeen2026-07-23T15:43:39.000ZLilly, with new data, to seek FDA approval of obesity drug retatrutidehttps://www.pharmaradar360.com/article/tranche-update-on-west-pharmaceutical-services-inc-s-equity-buyback-plan-announc-7a53d84f38ea95f8Pharma Surgeen2026-07-23T15:43:15.000ZTranche Update on West Pharmaceutical Services, Inc.'s Equity Buyback Plan announced on February 17, 2026.https://www.pharmaradar360.com/article/west-pharmaceutical-ceo-highlights-glp-1-and-biologics-momentum-2ae00f9edc3a2827Pharma Surgeen2026-07-23T15:32:26.000ZWest Pharmaceutical CEO Highlights GLP-1 And Biologics Momentumhttps://www.pharmaradar360.com/article/gsk-secures-first-lung-cancer-approval-validating-10-6bn-nuvalent-bet-8c759cd4c925e05ePharma Surgeen2026-07-23T15:25:43.000ZGSK secures first lung cancer approval, validating $10.6bn Nuvalent bethttps://www.pharmaradar360.com/article/breaking-news-eli-lilly-pays-38m-to-secure-land-for-massive-west-creek-pharma-fa-54c04de68812f619Pharma Surgeen2026-07-23T15:16:56.000ZBreaking News: Eli Lilly pays $38M to secure land for massive West Creek pharma facilityhttps://www.pharmaradar360.com/article/fugitive-doctor-on-run-for-21-years-was-living-as-an-l-a-biotech-executive-4e6432029125f332Pharma Surgeen2026-07-23T15:14:54.000ZFugitive doctor on run for 21 years was living as an L.A. biotech executivehttps://www.pharmaradar360.com/article/west-pharma-raises-profit-forecast-on-strong-demand-for-injectable-drug-componen-295eb448a343add7Pharma Surgeen2026-07-23T15:11:45.000ZWest Pharma raises profit forecast on strong demand for injectable drug componentshttps://www.pharmaradar360.com/article/legislation-to-cap-insulin-prices-improve-drug-safety-and-speed-access-to-biosim-7ca09808ef91ccb0Pharma Surgeen2026-07-23T15:06:41.000ZLegislation to Cap Insulin Prices, Improve Drug Safety, and Speed Access to Biosimilars Passes Senate HELP Committeehttps://www.pharmaradar360.com/article/fda-panel-confronting-peptide-controversy-e89af8290dd14a7aPharma Surgeen2026-07-23T15:03:06.000ZFDA panel confronting peptide controversyhttps://www.pharmaradar360.com/article/jyong-biotech-pursues-global-licensing-partnerships-for-bph-drug-01e8187bee7376a5Pharma Surgeen2026-07-23T15:03:00.000ZJyong Biotech pursues global licensing partnerships for BPH drughttps://www.pharmaradar360.com/article/why-is-west-pharmaceutical-services-stock-surging-today-by-investing-com-73cc5206d237c5f3Pharma Surgeen2026-07-23T14:54:42.000ZWhy is West Pharmaceutical Services stock surging today? By Investing.comhttps://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-8f4406ba700e5122Pharma Surgeen2026-07-23T14:52:32.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, June 2025 to June 2026https://www.pharmaradar360.com/article/jyong-biotech-highlights-multi-billion-dollar-global-bph-043814142c988f11Pharma Surgeen2026-07-23T14:52:00.000ZJyong Biotech Highlights Multi-Billion Dollar Global BPHhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-reports-earnings-results-for-the-second-quarter-7d3eafa921e481dfPharma Surgeen2026-07-23T14:41:20.000ZWest Pharmaceutical Services, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-telcon-rf-pharmaceutical-inc-krx-200230-1a4514b36ace5632Pharma Surgeen2026-07-23T14:40:14.000ZEnterprise value to revenue forward of TELCON RF PHARMACEUTICAL. Inc. – KRX:200230https://www.pharmaradar360.com/article/why-is-west-pharmaceutical-services-stock-surging-today-7807e1dfe0246e0dPharma Surgeen2026-07-23T14:34:20.000ZWhy is West Pharmaceutical Services stock surging today?https://www.pharmaradar360.com/article/medicines-eligible-for-northern-ireland-mhra-authorised-route-ea4846a98bf6c2a7Pharma Surgeen2026-07-23T14:31:59.000ZMedicines eligible for Northern Ireland MHRA Authorised Routehttps://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962cePharma Surgeen2026-07-23T14:30:04.000ZHigh consequence infectious disease: country specific riskhttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-07-23T14:30:04.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-07-23T14:30:04.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/mid-year-check-in-is-patient-affordability-getting-worse-9ca25119c88c2dcePharma Surgeen2026-07-23T14:26:59.000ZMid-Year Check-In: Is Patient Affordability Getting Worse?https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-epi-biotech-co-ltd-krx-446440-713c489f97df8491Pharma Surgeen2026-07-23T14:25:27.000ZEnterprise value to EBITDA forward of Epi Biotech Co., Ltd. – KRX:446440https://www.pharmaradar360.com/article/mabion-and-krisan-biotech-launch-partnership-for-next-gen-adcs-7a47cc1e0abcf982Pharma Surgeen2026-07-23T14:13:47.000ZMabion and KriSan Biotech Launch Partnership for Next-Gen ADCshttps://www.pharmaradar360.com/article/scancell-to-go-public-after-winning-reverse-merger-bid-for-troubled-neuphoria-067af9aba3952c1bPharma Surgeen2026-07-23T14:13:43.000ZScancell to go public after winning reverse merger bid for troubled Neuphoriahttps://www.pharmaradar360.com/article/pulsepoint-and-cmi-media-group-launch-the-first-agency-activation-of-hcp2dtc-inf-3b261f19a79d690bPharma Surgeen2026-07-23T14:01:00.000ZPulsePoint and CMI Media Group Launch the First Agency Activation of HCP2DTC Influence™https://www.pharmaradar360.com/article/most-wanted-fugitive-hid-out-for-21-years-as-a-biotech-exec-d8364014b7d3da7cPharma Surgeen2026-07-23T14:00:00.000ZMost-Wanted Fugitive Hid Out For 21 Years As A Biotech Exechttps://www.pharmaradar360.com/article/biogen-bets-newly-acquired-apellis-can-paper-over-leqembi-s-disappointing-sales-ada1a4a62fcc3389Pharma Surgeen2026-07-23T14:00:00.000ZBiogen bets newly acquired Apellis can paper over Leqembi's disappointing sales into 2027https://www.pharmaradar360.com/article/intrepidx-adds-hatch-waxman-ediscovery-leader-taylor-judd-to-expand-pharmaceutic-b68a91c47a365b58Pharma Surgeen2026-07-23T14:00:00.000ZIntrepidX Adds Hatch-Waxman eDiscovery Leader Taylor Judd to Expand Pharmaceutical Litigation and Corporate Legal Growthhttps://www.pharmaradar360.com/article/an-ai-biotech-just-reported-a-46-revenue-jump-and-its-first-recurring-platform-c-023e85cd51d07940Pharma Surgeen2026-07-23T13:53:09.000ZAn AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbershttps://www.pharmaradar360.com/article/artigo-o-verdadeiro-valor-da-inovacao-esta-na-jornada-do-paciente-3628d30617469bc8Pharma Surgeen2026-07-23T13:52:32.000ZArtigo: O verdadeiro valor da inovação está na jornada do pacientehttps://www.pharmaradar360.com/article/lilly-s-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-92d171b90ccb71cfPharma Surgeen2026-07-23T13:51:24.000ZLilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trialshttps://www.pharmaradar360.com/article/eli-lilly-is-acquiring-a-psychedelic-medicine-biotech-here-s-what-you-need-to-kn-029261212a25f35ePharma Surgeen2026-07-23T13:45:00.000ZEli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know.https://www.pharmaradar360.com/article/earnings-call-transcript-west-pharmaceutical-beats-q2-2026-estimates-lifts-outlo-b7ebaa88e892ea4aPharma Surgeen2026-07-23T13:42:05.000ZEarnings call transcript: West Pharmaceutical beats Q2 2026 estimates, lifts outlookhttps://www.pharmaradar360.com/article/west-pharmaceutical-wst-q2-earnings-taking-a-look-at-key-metrics-versus-estimate-4ab51a5093138ef4Pharma Surgeen2026-07-23T13:30:07.000ZWest Pharmaceutical (WST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimateshttps://www.pharmaradar360.com/article/full-transcript-west-pharmaceutical-servs-q2-2026-earnings-call-b0dfc77439169f26Pharma Surgeen2026-07-23T13:22:54.000ZFull Transcript: West Pharmaceutical Servs Q2 2026 Earnings Callhttps://www.pharmaradar360.com/article/egyptian-biotech-reme-d-raises-usd-1-45-m-pre-series-a-to-expand-molecular-diagn-59d69c2c84ae0174Pharma Surgeen2026-07-23T13:20:32.000ZEgyptian Biotech Reme-D Raises USD 1.45 M Pre-Series A To Expand Molecular Diagnosticshttps://www.pharmaradar360.com/article/what-to-know-about-the-7-peptides-being-reviewed-by-an-fda-panel-8985159c9a97ef8bPharma Surgeen2026-07-23T13:13:22.000ZWhat to know about the 7 peptides being reviewed by an FDA panelhttps://www.pharmaradar360.com/article/earnings-call-transcript-west-pharmaceutical-beats-q2-2026-estimates-lifts-outlo-72c0372df93f4610Pharma Surgeen2026-07-23T13:12:00.000ZEarnings call transcript: West Pharmaceutical beats Q2 2026 estimates, lifts outlookhttps://www.pharmaradar360.com/article/eli-lilly-is-acquiring-a-psychedelic-medicine-biotech-here-s-what-you-need-to-kn-4f667f36a85595c3Pharma Surgeen2026-07-23T13:05:00.000ZEli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know.https://www.pharmaradar360.com/article/an-ai-biotech-just-reported-a-46-revenue-jump-and-its-first-recurring-platform-c-cf6a60982c156803Pharma Surgeen2026-07-23T13:05:00.000ZAn AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbershttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090Pharma Surgeen2026-07-23T13:00:07.000ZWeekly all-cause mortality surveillance: 2026 to 2027https://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharma Surgeen2026-07-23T13:00:07.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharma Surgeen2026-07-23T13:00:07.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75Pharma Surgeen2026-07-23T13:00:07.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharma Surgeen2026-07-23T13:00:07.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharma Surgeen2026-07-23T13:00:07.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86Pharma Surgeen2026-07-23T13:00:07.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/level-of-attention-and-its-effects-on-risk-of-confusion-and-dilution-recent-eu-c-fb03f58c3fa5b78cPharma Surgeen2026-07-23T12:55:02.000ZLevel of attention and its effects on risk of confusion and dilution: recent EU case lawhttps://www.pharmaradar360.com/article/which-ishares-healthcare-etf-is-the-better-buy-diversified-ixj-or-biotech-focuse-0b699d2b7449f068Pharma Surgeen2026-07-23T12:49:00.000ZWhich iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB?https://www.pharmaradar360.com/article/tecvayli-talvey-reduced-the-risk-of-disease-progression-or-death-by-89-and-the-r-92bd04f1f69d0596Pharma Surgeen2026-07-23T12:44:29.000ZTECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myelomahttps://www.pharmaradar360.com/article/guidance-clinical-investigations-compiling-a-submission-b0150003dcab6d8fPharma Surgeen2026-07-23T12:43:36.000ZGuidance: Clinical investigations: compiling a submissionhttps://www.pharmaradar360.com/article/guidance-medical-devices-that-need-a-clinical-investigation-517dcad73a93591bPharma Surgeen2026-07-23T12:43:35.000ZGuidance: Medical devices that need a clinical investigationhttps://www.pharmaradar360.com/article/clinical-investigations-for-medical-devices-523f464bba1e6999Pharma Surgeen2026-07-23T12:43:34.000ZClinical investigations for medical deviceshttps://www.pharmaradar360.com/article/clinical-investigations-in-great-britain-e605b885c65902e1Pharma Surgeen2026-07-23T12:43:34.000ZClinical investigations in Great Britainhttps://www.pharmaradar360.com/article/guidance-approving-clinical-investigations-fa912ac542fa3debPharma Surgeen2026-07-23T12:43:33.000ZGuidance: Approving clinical investigationshttps://www.pharmaradar360.com/article/us-fda-panel-weighs-injectable-peptides-as-experts-demand-gray-market-guardrails-7f060c1025dcd114Pharma Surgeen2026-07-23T12:41:41.000ZUS FDA panel weighs injectable peptides as experts demand gray market guardrailshttps://www.pharmaradar360.com/article/canton-strategic-nasdaq-cntn-exits-gravitas-biotech-arm-with-3-5m-note-331daa10b2cebdd2Pharma Surgeen2026-07-23T12:40:53.000ZCanton Strategic (NASDAQ: CNTN) exits Gravitas biotech arm with $3.5M notehttps://www.pharmaradar360.com/article/why-is-west-pharmaceutical-services-stock-surging-today-dcff8d3d9b75f6a7Pharma Surgeen2026-07-23T12:40:00.000ZWhy is West Pharmaceutical Services stock surging today?https://www.pharmaradar360.com/article/cordis-project-omegatree-mas-10-enabled-metabolomics-and-ai-driven-precision-nut-c38dd6e3a0f19020Pharma Surgeen2026-07-23T12:36:04.000ZCORDIS project: OmegaTree: MAS-10® Enabled Metabolomics and AI-Driven Precision Nutrition and Health Analytics Platformhttps://www.pharmaradar360.com/article/cordis-project-ai-powered-prediction-of-cancer-therapy-response-using-ultrasound-73c740f3e4f31d58Pharma Surgeen2026-07-23T12:36:04.000ZCORDIS project: AI-POWERED PREDICTION OF CANCER THERAPY RESPONSE USING ULTRASOUND SHEAR WAVE ELASTOGRAPHYhttps://www.pharmaradar360.com/article/cordis-project-unlocking-multi-omics-analytics-for-european-precision-medicine-dfd25c574e164c3dPharma Surgeen2026-07-23T12:36:03.000ZCORDIS project: Unlocking Multi‑Omics Analytics for European Precision Medicinehttps://www.pharmaradar360.com/article/cordis-project-advancing-affordable-immune-based-multi-cancer-early-detection-49bbd91b713f9475Pharma Surgeen2026-07-23T12:36:03.000ZCORDIS project: Advancing Affordable, Immune-Based Multi-Cancer Early Detectionhttps://www.pharmaradar360.com/article/cordis-project-immuno-modulatory-platform-for-advanced-cll-therapy-bc04a151643966b1Pharma Surgeen2026-07-23T12:36:02.000ZCORDIS project: Immuno-Modulatory Platform for Advanced CLL Therapyhttps://www.pharmaradar360.com/article/boletin-sobre-productos-sanitarios-abril-junio-2026-734efc373548e49cPharma Surgeen2026-07-23T12:34:21.000ZBoletín sobre Productos Sanitarios. Abril – junio 2026https://www.pharmaradar360.com/article/fda-clears-johnson-johnson-s-surgical-robot-for-the-next-era-in-surgery-e5d3ea0d01300e97Pharma Surgeen2026-07-23T12:27:04.000ZFDA clears Johnson & Johnson’s surgical robot for ‘the next era in surgery’https://www.pharmaradar360.com/article/la-aemps-informa-de-la-deteccion-de-unidades-falsificadas-del-producto-cosmetico-9299b92adffd2de3Pharma Surgeen2026-07-23T12:27:02.000ZLa AEMPS informa de la detección de unidades falsificadas del producto cosmético Xhekpon cremahttps://www.pharmaradar360.com/article/west-pharmaceutical-services-nyse-wst-beats-expectations-in-strong-q2-cy2026-sto-9d3d4ff30a5e3019Pharma Surgeen2026-07-23T12:25:19.000ZWest Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soarshttps://www.pharmaradar360.com/article/eli-lilly-moves-closer-to-another-weight-loss-drug-retatrutide-clears-two-more-p-1cec4a0d0a83ac71Pharma Surgeen2026-07-23T12:23:00.000ZEli Lilly Moves Closer To Another Weight-Loss Drug: Retatrutide Clears Two More Phase 3 Trials Ahead Of FDA Filinghttps://www.pharmaradar360.com/article/west-pharmaceutical-services-releases-q2-2026-financial-results-061c87153992c7cdPharma Surgeen2026-07-23T12:19:20.000ZWest Pharmaceutical Services Releases Q2 2026 Financial Resultshttps://www.pharmaradar360.com/article/gerd-affects-about-20-of-u-s-population-as-jaqbo-nears-phase-3-884908e3091f5a34Pharma Surgeen2026-07-23T12:15:00.000ZGERD affects about 20% of U.S. population as JAQBO nears Phase 3https://www.pharmaradar360.com/article/bora-pharmaceuticals-and-onconic-therapeutics-sign-manufacturing-agreement-to-su-9ccd4c6ce31a19cfPharma Surgeen2026-07-23T12:15:00.000ZBora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tabletshttps://www.pharmaradar360.com/article/roche-diagnostics-growth-remains-muted-amid-china-headwinds-abf569d3f7180e62Pharma Surgeen2026-07-23T12:13:47.000ZRoche Diagnostics growth remains muted amid China headwindshttps://www.pharmaradar360.com/article/veraxa-biotech-names-christoph-erkel-as-chief-scientific-officer-8c326dda085c27c2Pharma Surgeen2026-07-23T12:04:39.000ZVeraxa Biotech names Christoph Erkel as chief scientific officerhttps://www.pharmaradar360.com/article/is-west-pharmaceutical-services-inc-wst-undervalued-after-q2-e-eb79f472e4aa3590Pharma Surgeen2026-07-23T12:01:04.000ZIs West Pharmaceutical Services Inc (WST) Undervalued After Q2 Ehttps://www.pharmaradar360.com/article/overstitchtm-suture-cinch-and-suture-cinch-long-d95e5f5bf4ccf6c2Pharma Surgeen2026-07-23T12:00:00.000ZOverStitch™ Suture Cinch and Suture Cinch–Longhttps://www.pharmaradar360.com/article/heartsine-samaritan-pad-sam-350p-sam-360p-sam-500p-membrane-tail-fff5a5c17128f0b3Pharma Surgeen2026-07-23T12:00:00.000ZHeartSine® Samaritan® PAD SAM 350P/SAM 360P/SAM 500P - Membrane Tailhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-nyse-wst-beats-expectations-in-strong-q2-cy2026-sto-18d05d3d219f8503Pharma Surgeen2026-07-23T11:58:00.000ZWest Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soarshttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-arrowhead-pharma-stock-rating-on-trial-data-477eaed4efa21a08Pharma Surgeen2026-07-23T11:58:00.000ZH.C. Wainwright reiterates Arrowhead Pharma stock rating on trial datahttps://www.pharmaradar360.com/article/la-aemps-inicia-los-ipt-de-los-medicamentos-que-han-obtenido-una-opinion-positiv-f84c630bbc1336e4Pharma Surgeen2026-07-23T11:57:24.000ZLa AEMPS inicia los IPT de los medicamentos que han obtenido una opinión positiva en la reunión del CHMP celebrada en juniohttps://www.pharmaradar360.com/article/la-aemps-inicia-los-ipt-de-los-medicamentos-que-han-obtenido-una-opinion-positiv-5de4fe4b69618dc0Pharma Surgeen2026-07-23T11:55:38.000ZLa AEMPS inicia los IPT de los medicamentos que han obtenido una opinión positiva en la reunión del CHMP celebrada en mayohttps://www.pharmaradar360.com/article/everything-you-need-to-know-about-clinical-trial-legislation-changes-afe49a912db358d5Pharma Surgeen2026-07-23T11:19:06.000ZEverything you need to know about clinical trial legislation changeshttps://www.pharmaradar360.com/article/biotech-stocks-lead-healthcare-s-overbought-list-as-earnings-picks-up-xlv-nysear-174f73b5ab81bbe6Pharma Surgeen2026-07-23T11:18:04.000ZBiotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA)https://www.pharmaradar360.com/article/form-8-k-west-pharmaceutical-serv-for-jul-23-1a75904bff342352Pharma Surgeen2026-07-23T11:16:25.000ZForm 8-K WEST PHARMACEUTICAL SERV For: Jul 23https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-q2-earnings-and-revenues-top-estimates-8ca265920e2f862aPharma Surgeen2026-07-23T11:15:04.000ZWest Pharmaceutical Services (WST) Q2 Earnings and Revenues Top Estimateshttps://www.pharmaradar360.com/article/veraxa-biotech-ag-appoints-christoph-erkel-ph-d-as-chief-scientific-officer-12a0226fae797c9cPharma Surgeen2026-07-23T11:12:00.000ZVERAXA Biotech AG Appoints Christoph Erkel, Ph.D., as Chief Scientific Officerhttps://www.pharmaradar360.com/article/rabies-post-exposure-risk-assessment-form-and-calendar-f8033f746394b277Pharma Surgeen2026-07-23T11:11:31.000ZRabies post exposure risk assessment form and calendarhttps://www.pharmaradar360.com/article/when-compounding-goes-bad-people-pay-the-price-9aad62a2ead0af1cPharma Surgeen2026-07-23T11:10:14.000ZWhen Compounding Goes Bad, People Pay the Pricehttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-buy-rating-from-rbc-0a03a4ab636037c7Pharma Surgeen2026-07-23T11:06:22.000ZSARTORIUS STEDIM BIOTECH : Buy rating from RBChttps://www.pharmaradar360.com/article/price-to-sales-forward-of-hyundai-pharmaceutical-co-ltd-krx-004310-004a6a4b5e95c5acPharma Surgeen2026-07-23T11:02:20.000ZPrice to sales forward of Hyundai Pharmaceutical Co., Ltd. – KRX:004310https://www.pharmaradar360.com/article/okyo-pharma-nasdaq-okyo-ceo-purchases-15-000-company-shares-2c3efab827bb6be0Pharma Surgeen2026-07-23T11:00:42.000ZOKYO Pharma (Nasdaq: OKYO) CEO purchases 15,000 company shareshttps://www.pharmaradar360.com/article/okyo-pharma-plans-global-phase-3-trial-for-about-111-patients-689a08b050099e2fPharma Surgeen2026-07-23T11:00:00.000ZOKYO Pharma Plans Global Phase 3 Trial for About 111 Patientshttps://www.pharmaradar360.com/article/lilly-s-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-f2ad33ed10f44d10Pharma Surgeen2026-07-23T10:45:00.000ZLilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1Chttps://www.pharmaradar360.com/article/eli-lilly-s-next-gen-obesity-drug-clears-phase-3-trials-but-heart-benefits-remai-27b79f270d007e8ePharma Surgeen2026-07-23T10:45:00.000ZEli Lilly’s Next-Gen Obesity Drug Clears Phase 3 Trials, But Heart Benefits Remain Unprovenhttps://www.pharmaradar360.com/article/lilly-s-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-401e431d29f58515Pharma Surgeen2026-07-23T10:45:00.000ZLilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1Chttps://www.pharmaradar360.com/article/west-pharmaceutical-raises-annual-profit-forecast-on-strong-demand-for-injectabl-6e8d5efac628275dPharma Surgeen2026-07-23T10:37:38.000ZWest Pharmaceutical raises annual profit forecast on strong demand for injectable drug componentshttps://www.pharmaradar360.com/article/initiate-prioritizes-early-stage-biotech-startups-with-proprietary-data-over-ai-0081d6cc8944f84aPharma Surgeen2026-07-23T10:36:26.000ZInitiate Prioritizes Early-Stage Biotech Startups With Proprietary Data Over AI Modelshttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-jiangsu-lianhuan-pharmaceutical-co-ltd-class-860037b1338ff2e2Pharma Surgeen2026-07-23T10:31:06.000ZEnterprise value to EBIT forward of Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A – SSE:600513https://www.pharmaradar360.com/article/exclusive-obesity-biotech-verdiva-hires-ex-metsera-cmo-as-crucial-readouts-near-dae9608479a5f1d9Pharma Surgeen2026-07-23T10:30:00.000ZExclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts nearhttps://www.pharmaradar360.com/article/gibson-dunn-guides-biotech-reverse-merger-dace43838c707a45Pharma Surgeen2026-07-23T10:29:06.000ZGibson Dunn guides biotech reverse mergerhttps://www.pharmaradar360.com/article/wst-west-pharmaceutical-services-inc-expects-q3-revenue-range-820-0m-835-0m-a8db3c4b8c169a81Pharma Surgeen2026-07-23T10:28:20.000Z(WST) West Pharmaceutical Services, Inc. Expects Q3 Revenue Range $820.0M - $835.0Mhttps://www.pharmaradar360.com/article/wst-west-pharmaceutical-services-expects-full-year-2026-adjusted-eps-range-8-85-92911e9a0c2b678ePharma Surgeen2026-07-23T10:27:26.000Z(WST) West Pharmaceutical Services Expects Full Year 2026 Adjusted EPS Range $8.85 - $9.05, vs. FactSet Est of $8.62https://www.pharmaradar360.com/article/earnings-flash-wst-west-pharmaceutical-services-inc-reports-q2-revenue-872-3m-vs-9122ad898aeb027ePharma Surgeen2026-07-23T10:26:55.000ZEarnings Flash (WST) West Pharmaceutical Services, Inc. Reports Q2 Revenue $872.3M, vs. FactSet Est of $840.0Mhttps://www.pharmaradar360.com/article/earnings-flash-wst-west-pharmaceutical-services-inc-posts-q2-adjusted-eps-2-37-p-77f2459e16724cb1Pharma Surgeen2026-07-23T10:25:51.000ZEarnings Flash (WST) West Pharmaceutical Services, Inc. Posts Q2 Adjusted EPS $2.37 per Share, vs. FactSet Est of $2.08https://www.pharmaradar360.com/article/militia-capital-management-llc-takes-3-50-million-position-in-teva-pharmaceutica-a7038f110b34b6acPharma Surgeen2026-07-23T10:25:21.000ZMilitia Capital Management LLC Takes $3.50 Million Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-earnings-beat-by-0-29-revenue-topped-estimates-d0bdb0851e3a4703Pharma Surgeen2026-07-23T10:17:35.000ZWest Pharmaceutical Services earnings beat by $0.29, revenue topped estimateshttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-07-23T10:16:54.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/us-intensifies-pressure-on-germany-over-pharmaceutical-pricing-policies-381575514ba09a21Pharma Surgeen2026-07-23T10:16:38.000ZUS intensifies pressure on Germany over pharmaceutical pricing policieshttps://www.pharmaradar360.com/article/west-pharmaceutical-q2-sales-beats-on-biologics-hpv-growth-raises-outlook-8a52b56471dfa5edPharma Surgeen2026-07-23T10:13:03.000ZWest Pharmaceutical Q2 sales beats on biologics, HPV growth; raises outlookhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-earnings-beat-by-0-29-revenue-topped-estimates-f4a8929d8134b097Pharma Surgeen2026-07-23T10:12:00.000ZWest Pharmaceutical Services earnings beat by $0.29, revenue topped estimateshttps://www.pharmaradar360.com/article/west-pharmaceutical-q2-earnings-snapshot-3c5961442b246cddPharma Surgeen2026-07-23T10:07:00.000ZWest Pharmaceutical: Q2 Earnings Snapshothttps://www.pharmaradar360.com/article/class-4-medicines-defect-notification-neuraxpharm-uk-ltd-tuzulby-prolonged-relea-ebc6bd413ec97df1Pharma Surgeen2026-07-23T10:03:27.000ZClass 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36https://www.pharmaradar360.com/article/pharmaceutical-company-warns-that-a-single-cigarette-butt-contaminates-a-thousan-1db33d05c6327745Pharma Surgeen2026-07-23T10:01:15.000ZPharmaceutical company warns that a single cigarette butt contaminates a thousand liters of waterhttps://www.pharmaradar360.com/article/brief-west-pharmaceutical-q2-adjusted-eps-usd-2-37-vs-ibes-estimate-usd-2-08-54a264c134d61168Pharma Surgeen2026-07-23T10:01:02.000ZBRIEF-West Pharmaceutical Q2 Adjusted EPS USD 2.37 Vs. IBES Estimate USD 2.08https://www.pharmaradar360.com/article/agricultural-biotech-firm-moa-technology-raises-22-2m-addc719615c4af6fPharma Surgeen2026-07-23T10:00:29.000ZAgricultural biotech firm Moa Technology raises £22.2mhttps://www.pharmaradar360.com/article/reply-to-post-recurrence-therapy-after-hepatectomy-clarifying-overall-survival-i-7915eba9cc237b93Pharma Surgeen2026-07-23T10:00:00.000ZReply to: Post-Recurrence Therapy After Hepatectomy: Clarifying Overall Survival in JCOG0603https://www.pharmaradar360.com/article/hypo-versus-standard-fractionated-locoregional-radiotherapy-of-patients-with-hig-245bfab126d8a080Pharma Surgeen2026-07-23T10:00:00.000ZHypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1https://www.pharmaradar360.com/article/into-the-unknown-regulatory-perspective-on-identifying-optimized-dosages-of-onco-508ad6db22258505Pharma Surgeen2026-07-23T10:00:00.000ZInto the Unknown: Regulatory Perspective on Identifying Optimized Dosages of Oncology Radiopharmaceutical Therapieshttps://www.pharmaradar360.com/article/post-recurrence-therapy-after-hepatectomy-clarifying-overall-survival-in-jcog060-d8eeeabc4e521dd7Pharma Surgeen2026-07-23T10:00:00.000ZPost-Recurrence Therapy After Hepatectomy: Clarifying Overall Survival in JCOG0603https://www.pharmaradar360.com/article/cheiron-lands-8-million-seed-for-ai-driven-development-platform-ca273dbfd6973ac6Pharma Surgeen2026-07-23T09:54:41.000ZCheiron lands $8 million seed for AI-driven development platformhttps://www.pharmaradar360.com/article/la-aemps-habilita-el-procedimiento-para-realizar-la-comunicacion-previa-de-la-fa-5b4cf34ab02ce1fcPharma Surgeen2026-07-23T09:34:28.000ZLa AEMPS habilita el procedimiento para realizar la comunicación previa de la fabricación in house de productos sanitarios para diagnóstico in vitrohttps://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-september-2025-f4f2b3e518324c08Pharma Surgeen2026-07-23T09:30:03.000ZAdult social care client level data, England: quarterly update to September 2025https://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-december-2025-aa0869c7cb4e90dcPharma Surgeen2026-07-23T09:30:03.000ZAdult social care client level data, England: quarterly update to December 2025https://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-1b4c313e4093d4bbPharma Surgeen2026-07-23T09:30:03.000ZAdult social care client level data, England: quarterly updatehttps://www.pharmaradar360.com/article/etcamah-clears-europe-with-us-verdict-on-breast-cancer-switch-pending-41b5b4b16f17d8b3Pharma Surgeen2026-07-23T09:26:38.000ZEtcamah clears Europe with US verdict on breast cancer switch pendinghttps://www.pharmaradar360.com/article/pharmaceutical-technology-90cb93202db361cbPharma Surgeen2026-07-23T09:17:52.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/toni-daa-dhaba-11-others-face-fda-action-over-hygiene-lapses-6d176758cd89b55ePharma Surgeen2026-07-23T09:13:14.000ZToni Daa Dhaba, 11 others face FDA action over hygiene lapseshttps://www.pharmaradar360.com/article/lundbeck-receives-fda-advantage-for-new-sleep-drug-candidate-88b2e35c3ad3f090Pharma Surgeen2026-07-23T09:09:00.000ZLundbeck receives FDA advantage for new sleep drug candidatehttps://www.pharmaradar360.com/article/substantially-better-than-before-why-india-has-golden-opportunity-to-build-on-in-9780adff623c72d1Pharma Surgeen2026-07-23T09:00:00.000Z‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D winshttps://www.pharmaradar360.com/article/fda-panel-considers-easing-peptide-restrictions-a0bd7ef3013d2d2fPharma Surgeen2026-07-23T09:00:00.000ZFDA panel considers easing peptide restrictionshttps://www.pharmaradar360.com/article/fda-panel-backs-easier-access-to-peptides-6577502417ad171dPharma Surgeen2026-07-23T09:00:00.000ZFDA panel backs easier access to peptideshttps://www.pharmaradar360.com/article/dhsc-counter-fraud-strategy-2026-to-2029-bf32b1a2df0da88fPharma Surgeen2026-07-23T08:50:05.000ZDHSC counter-fraud strategy: 2026 to 2029https://www.pharmaradar360.com/article/measles-epidemiology-2023-to-2026-1387e9c40489bd37Pharma Surgeen2026-07-23T08:30:05.000ZMeasles epidemiology 2023 to 2026https://www.pharmaradar360.com/article/shiga-toxin-producing-escherichia-coli-stec-annual-totals-79e6aae9d6d8d0b8Pharma Surgeen2026-07-23T08:30:04.000ZShiga toxin-producing Escherichia coli (STEC): annual totalshttps://www.pharmaradar360.com/article/join-asca2026-in-malaysia-c85b65ec9adf96cdPharma Surgeen2026-07-23T08:29:50.000ZJoin ASCA2026 in Malaysiahttps://www.pharmaradar360.com/article/strong-sales-of-vyvgart-push-results-of-biotech-company-argenx-83fc7cb51313305ePharma Surgeen2026-07-23T08:27:30.000ZStrong sales of Vyvgart push results of biotech company Argenxhttps://www.pharmaradar360.com/article/burning-rock-biotech-limited-sponsored-adr-bnr-shares-sold-by-crcm-lp-299638a0177bd605Pharma Surgeen2026-07-23T08:26:42.000ZBurning Rock Biotech Limited Sponsored ADR $BNR Shares Sold by Crcm LPhttps://www.pharmaradar360.com/article/la-aemps-participa-en-el-proyecto-vac-med-para-fortalecer-las-capacidades-regula-1b405d7678a50d50Pharma Surgeen2026-07-23T08:20:20.000ZLa AEMPS participa en el proyecto Vac-Med para fortalecer las capacidades regulatorias de América Latina y Caribehttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-jiangsu-lianhuan-pharmaceutical-co-ltd-cla-e1b4c77197015c60Pharma Surgeen2026-07-23T08:08:59.000ZEnterprise value to EBITDA forward of Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A – SSE:600513https://www.pharmaradar360.com/article/uk-and-switzerland-collaborate-to-shape-the-future-of-space-enabled-pharmaceutic-689cebd047fa3a98Pharma Surgeen2026-07-23T08:00:00.000ZUK and Switzerland collaborate to shape the future of space-enabled pharmaceuticalshttps://www.pharmaradar360.com/article/io-biotech-founder-brings-key-lessons-to-new-top-job-i-can-get-through-a-crisis-a2298942c0d1b0ebPharma Surgeen2026-07-23T07:51:00.000ZIO Biotech founder brings key lessons to new top job: “I can get through a crisis”https://www.pharmaradar360.com/article/missed-ai-memory-bull-run-biotech-may-be-the-next-breakout-trade-but-retail-sent-863d61fdca8deb59Pharma Surgeen2026-07-23T07:46:29.000ZMissed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lowerhttps://www.pharmaradar360.com/article/interview-how-tragedy-changed-the-fda-d30cb80e75f0b47aPharma Surgeen2026-07-23T07:44:42.000ZInterview: How Tragedy Changed the FDAhttps://www.pharmaradar360.com/article/ai-biotech-startup-cheiron-launches-8-million-seed-round-430a553d6e4c9d71Pharma Surgeen2026-07-23T07:02:52.000ZAI biotech startup Cheiron launches $8 million seed roundhttps://www.pharmaradar360.com/article/arthex-biotech-publishes-first-demonstration-of-improvement-in-a-dm1-related-beh-58a9d0db863a4b97Pharma Surgeen2026-07-23T07:00:00.000ZARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)https://www.pharmaradar360.com/article/jamjoom-pharma-updates-on-non-binding-term-sheet-with-pharmaceutical-investment-917d566624c65d24Pharma Surgeen2026-07-23T06:52:00.000ZJamjoom Pharma Updates On Non-Binding Term Sheet With Pharmaceutical Investment Companyhttps://www.pharmaradar360.com/article/cash-flow-from-investing-activities-of-teh-seng-pharmaceutical-mfg-co-ltd-tpex-7-be404f7d36617888Pharma Surgeen2026-07-23T06:27:44.000ZCash flow from investing activities of Teh Seng Pharmaceutical Mfg Co Ltd – TPEX:7860https://www.pharmaradar360.com/article/bmc-hq-canteen-sealed-by-fda-over-food-safety-lapses-dead-fly-plastic-thread-fou-056b5df98064812dPharma Surgeen2026-07-23T06:12:51.000ZBMC HQ canteen sealed by FDA over food safety lapses; dead fly, plastic thread found in foodhttps://www.pharmaradar360.com/article/world-melting-point-meter-market-analysis-forecast-size-trends-and-insights-c70e375cf8dcaa24Pharma Surgeen2026-07-23T05:56:13.000ZWorld Melting Point Meter - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/kolon-tissuegene-hits-daily-loss-limit-for-third-straight-session-after-u-s-phas-665c9f460472005bPharma Surgeen2026-07-23T05:55:59.000ZKolon TissueGene Hits Daily Loss Limit for Third Straight Session After U.S. Phase 3 Failurehttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-sinopep-allsino-bio-pharmaceutical-co-ltd-0c902ff85f3e230fPharma Surgeen2026-07-23T05:49:31.000ZEnterprise value to EBITDA forward of Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A – SSE:688076https://www.pharmaradar360.com/article/phase-3-trial-of-zydus-desidustat-begins-with-hope-for-sickle-cell-patients-301f009626200ac6Pharma Surgeen2026-07-23T05:48:36.000ZPhase 3 trial of Zydus' Desidustat begins with hope for sickle cell patientshttps://www.pharmaradar360.com/article/opinion-trump-s-generic-drug-tariffs-will-drive-up-pharmaceutical-prices-9e17120513f83a99Pharma Surgeen2026-07-23T05:29:35.000ZOpinion | Trump’s generic drug tariffs will drive up pharmaceutical priceshttps://www.pharmaradar360.com/article/zydus-lifesciences-gets-green-light-for-phase-iii-desidustat-trial-in-sickle-cel-dff20607dbfa10acPharma Surgeen2026-07-23T05:02:20.000ZZydus Lifesciences Gets Green Light For Phase III Desidustat Trial In Sickle Cell Patientshttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-continues-positive-development-and-expands-profitable-g-c3a2fafba66805aaPharma Surgeen2026-07-23T05:02:05.000ZSartorius Stedim Biotech continues positive development and expands profitable growthhttps://www.pharmaradar360.com/article/ad-hoc-announcement-pursuant-to-art-53-lr-roche-s-strong-momentum-continues-in-t-1d467bfa5526285cPharma Surgeen2026-07-23T05:00:00.000Z[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franchttps://www.pharmaradar360.com/article/innate-pharma-to-participate-in-a-bladder-cancer-panel-at-the-btig-virtual-biote-a604f44a57062f31Pharma Surgeen2026-07-23T05:00:00.000ZInnate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conferencehttps://www.pharmaradar360.com/article/2026-de8df641c0d48b6cPharma Surgeen2026-07-23T05:00:00.000Zエフ・ホフマン・ラ・ロシュの2026年中間決算発表についてhttps://www.pharmaradar360.com/article/f-hoffmann-la-roche-announces-half-year-results-2026-21af9e371ac6b451Pharma Surgeen2026-07-23T05:00:00.000ZF. Hoffmann-La Roche Announces Half Year Results 2026https://www.pharmaradar360.com/article/is-a-single-patient-kb801-outcome-quietly-reframing-krystal-biotech-s-clinical-n-9187b800db1c8efaPharma Surgeen2026-07-23T04:59:13.000ZIs A Single-Patient KB801 Outcome Quietly Reframing Krystal Biotech's Clinical Narrative (KRYS)?https://www.pharmaradar360.com/article/chinese-ambassador-to-zimbabwe-zhou-ding-visits-china-aided-zimbabwe-national-ph-a8096521792b7eefPharma Surgeen2026-07-23T04:55:00.000ZChinese Ambassador to Zimbabwe Zhou Ding Visits China-aided Zimbabwe National Pharmaceutical Warehousehttps://www.pharmaradar360.com/article/fda-reviews-peptide-injections-favored-by-rfk-jr-and-wellness-influencers-9604737788e22287Pharma Surgeen2026-07-23T04:51:05.000ZFDA reviews peptide injections favored by RFK Jr. and wellness influencershttps://www.pharmaradar360.com/article/how-venture-capital-can-unlock-biotech-s-long-term-value-42ea3ab2aaaa857fPharma Surgeen2026-07-23T04:48:28.000ZHow venture capital can unlock biotech’s long-term valuehttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-tonghua-dongbao-pharmaceutical-co-ltd-class-a-sse-6-656b01c9b1388bc4Pharma Surgeen2026-07-23T04:42:26.000ZPrice to earnings forward of Tonghua Dongbao Pharmaceutical Co., Ltd. Class A – SSE:600867